Promising efficacy and a low rate of cytokine release syndrome with ABBV-383 in patients with released/refractory multiple myeloma Admin December 26, 2024
CD19 expression is maintained after treatment with tafasitamab in patients with DLBCL Admin December 26, 2024
Tafasitamab-lenalidomide for relapsed/refractory DLBCL: real-world data from the United States Admin December 26, 2024
Tafasitamab-lenalidomide for relapsed/refractory DLBCL: real-world data from the GELTAMO study Admin December 26, 2024
Efficacy and safety of selinexor-pomalidomide-dexamethasone in patients with released/refractory multiple myeloma Admin December 26, 2024
Adding blinatumomab to consolidation therapy in older newly-diagnosed patients with Philadelphia-negative B-ALL Admin December 26, 2024
Isa-VRd in transplant-ineligible patients with newly diagnosed multiple myeloma and high-risk features Admin December 26, 2024
Isatuximab-lenalidomide-bortezomib and low-dose dexamethasone: an effective steroid sparing regimen for transplant-ineligible MM Admin December 26, 2024
